| MDRNA (NASDAQ:MRNA) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $0.85 | 52 Week High | $3.55 | ||
| Open | $0.82 | 52 Week Low | $0.21 | ||
| Day High | $0.84 | P/E | N/A | ||
| Day Low | $0.80 | EPS | $-0.54 | ||
| Volume | 211,120 | ||||
| More MRNA Info: Chart SEC Filings Profile Historical Options | |||||
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| SYMC | 4 | EFUT | 4 |
| GRH | 3 | PAR | 3 |
| SAY | 3 | LEA | 3 |
| DISK | 3 | PERY | 3 |
| DRIV | 3 | ALVR | 3 |
| AXL | 3 | FCEL | 3 |
on Nov 11, 2009
at 10:53 AM OPINION SOMETIMES DO COUNT(MRNA) http://www.medicalnewstoday.com/youropinions.php?opinionid=43299 REALITY IS HARD TO SWALLOW SOMETIMES GOOD LUCK TO 'MRNA' SHAREHOLDERS AND I HOPE THEY WAKE UP SOON!
Article: MDRNA (MRNA) Reports on DiLA2's Delivery of UsiRNA to Tumors in Vivo
on Sep 8, 2009
at 10:38 AM UPDATE:SEPTEMBER 8TH ON 'MRNA' THESTREET.COM HOT BIOTECHS NEXT WEEK:BIO BUZZ BY ADAM FEUERSTEIN Hot Biotech Events for Next Week: BioBuzz 09/04/09 - 07:50 AM EDT See All 2 Comments ELN , GERN , AGEN , BIIB , OSIR , GNTA.OB , VVUS Adam Feuerstein My comment to Adam, was why did he leave 'MRNA" out of his article? Below is his response for the entire HERD to read James - No slight intended by leaving out MDRNA. I'm sure you realize that dozens of companies are presenting next week. I can't mention them all. Re: MDRNA --I did see the CEO present last month at the Canaccord Adams conference, and let me say bluntly that he needs serious help with corporate messaging. I don't think I've ever sat through a more dense (and boring) investor presentation. I get it that RNAi isn't the easiest technology to explain simply, but the last thing I want at an investor conference is a 20-minute biochemistry lesson, which is what i heard. Seriously, there were people in the room falling asleep. ALWAYS NEWS ANNOUNCEMENTS, BUT DO THEY PRINT WHAT THEIR OWN WRITERS SAY ABOUT 'MRNA' WHEN ASKED A QUESTION.
Article: MDRNA, Inc. (MRNA) Reports Positive In Vivo Data Demonstrating That Its UsiRNAs Are Highly Potent Against Metabolic and Oncology Targets
on Aug 31, 2009
at 08:49 AM ANALYSTS ON 'MRNA' AFTER THREE CONSECUTIVE YEARS OF BEING DEAD WRONG ON THEIR TARGET PRICES, THEY STILL ARE ISSUING A $4.00 TARGET PRICE. WHY? THESE PEOPLE SHOULD BE INVESTIGATED! CLOSED $1.40 FRIDAY. MRNA-TODAY AUG.31,2009 Bid: 1.35 x 500 Ask: 1.62 x 100
Article: MDRNA, Inc. (MRNA) Announces Full Repayment of GE Capital Debt
on Aug 7, 2009
at 10:59 AM MRNA(FEEDBACK)POSITIVE IN VIVO REPORT MRNA-AUG.7th- Nice news but still pre-clinical stage company. Repetative news, no earnings,no revenue, and 4-6 years away from possible approvals.That is why it is $1.48 up down stock price and channeling experts making profits, but it always was and still is a toture stock for any long investors.
Article: MDRNA, Inc. (MRNA) Reports Positive In Vivo Data Demonstrating That Its UsiRNAs Are Highly Potent Against Metabolic and Oncology Targets
on Aug 3, 2009
at 03:40 PM Huron Consulting under investigation Hi All – Thought I’d provide a quick link for any investors reading this piece – I work for a law firm that’s investigating Huron on behalf of investors. You can learn more about the investigation here – www.hbsslaw.com/huron. HBSS is looking into possible issues with over-reported earnings, kickbacks to company insiders, and how and when the company notified shareholders.
Article: Morning Movers 8/3: KERX, TSPT, TSEM, ICAD, AMFI Higher; HURN, RPRX, ADAT, SVNT Lower